Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clolar Launching For Pediatric ALL; Genzyme, FDA Discussing Adult Studies

Executive Summary

Genzyme will employ a sales force of less than 10 to launch Clolar for pediatric acute lymphoblastic leukemia in January

You may also be interested in...



Clolar Confirmatory Study Should Be In Early-Relapse Patients, Cmte. Says

Genzyme's confirmatory study for Clolar should be conducted in an early-relapse leukemia pediatric population, members of the Oncologic Drugs Advisory Committee Pediatric Subcommittee said Oct. 20

Clolar Confirmatory Study Should Be In Early-Relapse Patients, Cmte. Says

Genzyme's confirmatory study for Clolar should be conducted in an early-relapse leukemia pediatric population, members of the Oncologic Drugs Advisory Committee Pediatric Subcommittee said Oct. 20

Accelerated Approval Requests Based On Low Efficacy Frustrate FDA

FDA appears to be increasingly frustrated with sponsors who seek accelerated approval based upon the lowest possible efficacy standard

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel